EN | RU
EN | RU

Help Support

Back

Novel Tofacitinib Generics: Pioneering 50% csDMARD-Sparing, 93% NSAID-Sparing Effect

Axial spondyloarthritis Axial spondyloarthritis
Axial spondyloarthritis Axial spondyloarthritis

What's new?

Tofacitinib generics display good safety and efficacy in patients with axial spondyloarthritis.

Tofacitinib generics offer a practical solution for patients with axial spondyloarthritis (axSpA) by reducing the need for conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and non-steroidal anti-inflammatory drugs (NSAIDs), outlined a study issued in October 2023 in 'Cureus'. axSpA presents a challenging landscape for treatment. Tofacitinib, initially validated through clinical trials, has emerged as a viable therapeutic option for axSpA.

However, the real-world efficacy of Tofacitinib generics in managing axSpA, especially in India where csDMARDs are widely used, remains a subject of limited exploration. This study aimed to investigate the possibility of Tofacitinib generics in reducing the reliance on csDMARDs and NSAIDs in the axSpA population. Conducted retrospectively in a real-world clinical setting, the study involved the analysis of data from 9 rheumatology centres across India.

A total of 168 active axSpA patients were included, who were prescribed generic Tofacitinib dosed 5 mg given two times every day, along with csDMARDs and NSAIDs over 6 months.

The primary objective was to assess the ability of Tofacitinib generics to spare the use of csDMARDs and NSAIDs, with the secondary goal of assessing its safety and efficacy after 6 months. The median Ankylosing Spondylitis Disease Activity Score (ASDAS) erythrocyte sedimentation rate (ESR) score of the patients under consideration was 3.91.

Among the patients receiving Tofacitinib generics, 72% were concurrently administered csDMARDs (Methotrexate/Sulfasalazine/both), and 53.6% were also receiving NSAIDs. Impressively, Tofacitinib generics exhibited substantial sparing effects, as shown in Table 1:

Notably, mild and well-tolerated adverse events were reported. About 57.9% of patients had achieved clinically significant improvements in their ASDAS ESR scores, with a median decrease of 2.02 after 6 months. This study unveils a novel dimension in the management of axSpA with Tofacitinib generics.

Source:

Cureus

Article:

Do Tofacitinib Generics Exhibit Conventional Synthetic Disease-Modifying Anti-rheumatic Drug and Non-steroidal Anti-inflammatory Drug-Sparing Ability in the Management of Axial Spondyloarthritis?

Authors:

Arvind Ganapati et al.

Comments (1)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: